• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Open Access Articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Expert consensus statements for the management of COVID-19-related acute respiratory failure using a Delphi method

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Author
    Nasa, Prashant
    Azoulay, Elie
    Khanna, Ashish K
    Jain, Ravi
    Gupta, Sachin
    Javeri, Yash
    Juneja, Deven
    Rangappa, Pradeep
    Sundararajan, Krishnaswamy
    Alhazzani, Waleed
    Antonelli, Massimo
    Arabi, Yaseen M
    Bakker, Jan
    Brochard, Laurent J
    Deane, Adam M
    Du, Bin
    Einav, Sharon
    Esteban, Andrés
    Gajic, Ognjen
    Galvagno, Samuel M
    Guérin, Claude
    Jaber, Samir
    Khilnani, Gopi C
    Koh, Younsuck
    Lascarrou, Jean-Baptiste
    Machado, Flavia R
    Malbrain, Manu L N G
    Mancebo, Jordi
    McCurdy, Michael T
    McGrath, Brendan A
    Mehta, Sangeeta
    Mekontso-Dessap, Armand
    Mer, Mervyn
    Nurok, Michael
    Park, Pauline K
    Pelosi, Paolo
    Peter, John V
    Phua, Jason
    Pilcher, David V
    Piquilloud, Lise
    Schellongowski, Peter
    Schultz, Marcus J
    Shankar-Hari, Manu
    Singh, Suveer
    Sorbello, Massimiliano
    Tiruvoipati, Ravindranath
    Udy, Andrew A
    Welte, Tobias
    Myatra, Sheila N
    Show allShow less

    Date
    2021-03-16
    Journal
    Critical care (London, England)
    Publisher
    Springer Nature
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1186/s13054-021-03491-y
    Abstract
    Using a Delphi process, an international panel of 39 experts developed clinical practice statements on the respiratory management of C-ARF in areas where evidence is absent or limited. Agreement was defined as achieved when > 70% experts voted for a given option on the Likert scale statement or > 80% voted for a particular option in multiple-choice questions. Stability was assessed between the two concluding rounds for each statement, using the non-parametric Chi-square (χ2) test (p < 0·05 was considered as unstable).
    Keyword
    COVID 19 invasive mechanical ventilation
    COVID-19 acute respiratory distress syndrome
    COVID-19 high flow nasal oxygen
    COVID-19 respiratory management
    COVID-19 ventilatory management
    Respiratory distress syndrome adult
    Identifier to cite or link to this item
    http://hdl.handle.net/10713/15104
    ae974a485f413a2113503eed53cd6c53
    10.1186/s13054-021-03491-y
    Scopus Count
    Collections
    UMB Open Access Articles
    UMB Coronavirus Publications

    entitlement

    Related articles

    • [Position Paper for the State of the Art Application of Respiratory Support in Patients with COVID-19 - German Respiratory Society].
    • Authors: Pfeifer M, Ewig S, Voshaar T, Randerath W, Bauer T, Geiseler J, Dellweg D, Westhoff M, Windisch W, Schönhofer B, Kluge S, Lepper PM
    • Issue date: 2020 Jun
    • Emergency Department Management of Severe Hypoxemic Respiratory Failure in Adults With COVID-19.
    • Authors: Wilcox SR, Condella A
    • Issue date: 2021 Jun
    • Position Paper for the State-of-the-Art Application of Respiratory Support in Patients with COVID-19.
    • Authors: Pfeifer M, Ewig S, Voshaar T, Randerath WJ, Bauer T, Geiseler J, Dellweg D, Westhoff M, Windisch W, Schönhofer B, Kluge S, Lepper PM
    • Issue date: 2020
    • Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS.
    • Authors: Lentz S, Roginski MA, Montrief T, Ramzy M, Gottlieb M, Long B
    • Issue date: 2020 Oct
    • Optimising Ventilator Use during the COVID-19 Pandemic.
    • Authors: Sheikh S, Baig MA
    • Issue date: 2020 Jun

    Related items

    Showing items related by title, author, creator and subject.

    • Thumbnail

      Immune Correlates of COVID-19 Control

      Poonia, Bhawna; Kottilil, Shyam (Frontiers Media S.A., 2020-09-29)
      COVID-19 caused by SARS CoV2 emerged in China at the end of 2019 and soon become a pandemic. Since the virus is novel, pre-existing CoV2-specific immunity is not expected to exist in humans, although studies have shown presence of CoV2 cross-reactive T cells in unexposed individuals. Lack of effective immunity in most individuals along with high infectiousness of the virus has resulted in massive global public health emergency. Intense efforts are on to study viral pathogenesis and immune response to help guide prophylactic and therapeutic interventions as well as epidemiological assessments like transmission modeling. To develop an effective vaccine or biologic therapeutic, it is critical to understand the immune correlates of COVID-19 control. At the same time, whether immunity in recovered individuals is effective for preventing re-infection will be important for informing interventions like social distancing. Key questions that are being investigated regarding immune response in COVID-19 which will help these efforts include, investigations of immune response that distinguishes patients with severe versus mild infection or those that recover relative to those that succumb, durability of immunity in recovered patients and relevance of developed immunity in a cured patient for protection against re-infection as well as value of convalescent plasma from recovered patients as a potential therapeutic modality. This is a broad and rapidly evolving area and multiple reports on status of innate and adaptive immunity against SARS-CoV2 are emerging on a daily basis. While many questions remain unanswered for now, the purpose of this focused review is to summarize the current understanding regarding immune correlates of COVID-19 severity and resolution in order to assist researchers in the field to pursue new directions in prevention and control. © Copyright © 2020 Poonia and Kottilil.
    • Thumbnail

      Review of COVID-19 Myocarditis in Competitive Athletes: Legitimate Concern or Fake News?

      Khan, Zulqarnain; Na, Jonathan S; Jerome, Scott (Frontiers Media S.A., 2021-07-14)
    • Thumbnail

      Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults.

      Fraiman, Joseph; Erviti, Juan; Jones, Mark; Greenland, Sander; Whelan, Patrick; Kaplan, Robert M; Doshi, Peter (Elsevier, 2022-08-30)
      Introduction: In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials. Methods: Secondary analysis of serious adverse events reported in the placebo-controlled, phase III randomized clinical trials of Pfizer and Moderna mRNA COVID-19 vaccines in adults (NCT04368728 and NCT04470427), focusing analysis on Brighton Collaboration adverse events of special interest. Results: Pfizer and Moderna mRNA COVID-19 vaccines were associated with an excess risk of serious adverse events of special interest of 10.1 and 15.1 per 10,000 vaccinated over placebo baselines of 17.6 and 42.2 (95 % CI -0.4 to 20.6 and -3.6 to 33.8), respectively. Combined, the mRNA vaccines were associated with an excess risk of serious adverse events of special interest of 12.5 per 10,000 vaccinated (95 % CI 2.1 to 22.9); risk ratio 1.43 (95 % CI 1.07 to 1.92). The Pfizer trial exhibited a 36 % higher risk of serious adverse events in the vaccine group; risk difference 18.0 per 10,000 vaccinated (95 % CI 1.2 to 34.9); risk ratio 1.36 (95 % CI 1.02 to 1.83). The Moderna trial exhibited a 6 % higher risk of serious adverse events in the vaccine group: risk difference 7.1 per 10,000 (95 % CI -23.2 to 37.4); risk ratio 1.06 (95 % CI 0.84 to 1.33). Combined, there was a 16 % higher risk of serious adverse events in mRNA vaccine recipients: risk difference 13.2 (95 % CI -3.2 to 29.6); risk ratio 1.16 (95 % CI 0.97 to 1.39). Discussion: The excess risk of serious adverse events found in our study points to the need for formal harm-benefit analyses, particularly those that are stratified according to risk of serious COVID-19 outcomes. These analyses will require public release of participant level datasets.
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.